Novartis

Basel, Switzerland
Find alternatives to Novartis for CAR-T →
In-house manufacturer
421 confirmed programs · 118 sponsors · Last scored 2026-11-02
85.4
Signal Score
✓ FDA Inspections (19) ✓ Clinical Trials (137) ✓ SEC Filings (35) ✓ Press (20) ✓ EMA GMP (50) ✓ MHRA GMP (1) ✓ HC GMP (36)

Quick Facts: Novartis

Signal Score
85.4/100 (as of 2026-11-02)
Quality Compliance
97.4/100 — Clean EMA record: 50 active GMP certificates (no deductions)
Headquarters
Basel, Switzerland
Modalities
CAR-T, Gene Therapy
Active Programs
421 confirmed from ClinicalTrials.gov across 118 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Novartis

Kymriah manufacturer.

Signal Score & Pillar Breakdown

Quality Compliance 97.4
Clean EMA record: 50 active GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP, MHRA GMDP
Clean EMA record: 50 active GMP certificates (no deductions)
FDA Inspections19 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2026-06-24)
EMA GMP Certificates50 on record
MHRA GMP Certificates1 on record
Most Recent HC OutcomeCompliant · 2025-12-18
HC Attribution36 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean EMA record: 50 active GMP certificates (no deductions)
Operations 94.7
421 active programs across 118 sponsors
Modalities: CAR-T, Gene Therapy
280 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
421 active programs across 118 sponsors · Modalities: CAR-T, Gene Therapy · 280 programs in advanced phases (Phase 2/3)
Programs 421
Sponsors118
ModalitiesCAR-T, Gene Therapy
421 active programs across 118 sponsors
Modalities: CAR-T, Gene Therapy
280 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07676877 Lymphodepletion With Low Dose Total Body Irradiation Before... PHASE1 Not Yet Recruiting
NCT07443137 CAR-T ceLL for Eradication of Active Residual Disease in LBCL... PHASE1 Not Yet Recruiting
NCT07493408 Asciminib & Standard-of-Care Integration in Maintenance... PHASE2 Not Yet Recruiting
NCT07250087 Asciminib Maintenance Therapy Following alloHCT or CAR T to... PHASE1 Recruiting
NCT06964958 177LuPSMA in Renal Cell Carcinoma PHASE2 Active Not Recruiting
NCT05469828 Crizanlizumab Improves Tissue Oxygen Supply Demand Matching... PHASE1/PHASE2 Not Yet Recruiting
NCT06456138 Trametinib Plus Anlotinib Combined With Tislelizumab in... PHASE1/PHASE2 Not Yet Recruiting
NCT06430671 Peptide-coupled Red Blood Cells for the Treatment of Multiple... PHASE1 Completed
NCT06395402 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry PHASE2 Recruiting
NCT05567055 Central Nervous System Efficacy of Capmatinib in NSCLC With... PHASE2 Withdrawn
View all 137 programs →
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 75.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
35 SEC filings with industry mentions on record (shown, not scored)
SEC Filings35 with industry mentions (not scored)
Publicly traded — financial transparency
Capacity 63.0
3 manufacturing sites
Sites: Morris Plains, NJ, Stein, Switzerland, Les Ulis, France
Source: company profiles (manufacturing sites, modality breadth)
3 manufacturing sites
Press Signals20 articles (not scored)
3 manufacturing sites

Novartis FDA Inspection History

2026-06
2025-12
2025-12
2025-06
2025-03
2024-11
2024-08
2024-08
2024-06
2024-06
2024-02
2023-08
2023-06
2023-01
2022-12
2022-09
2022-08
2025-07
2023-08
NAI VAI OAI
Date Site Type 483 citations posted Classification
2026-06-24
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2025-12-18
Novartis Pharma AG
Basel Town Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2025-12-09
Novartis d.o.o.
Ljubljana Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2025-06-25
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2025-03-03
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Drug Quality Assurance Not posted No Action Indicated (NAI)
2024-11-19
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2024-08-29
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2024-08-08
Novartis Pharmaceuticals Corporation
Morris Plains, New Jersey Company-level
Human Cellular, Tissue, and Gene Therapies Yes Voluntary Action Indicated (VAI)
2024-06-27
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2024-06-04
Novartis Pharma AG
Basel Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2024-02-09
Novartis d.o.o.
Ljubljana Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2023-08-21
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Bioresearch Monitoring Yes Voluntary Action Indicated (VAI)
2023-06-13
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2023-01-25
Novartis d.o.o.
Ljubljana Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2022-12-09
Novartis Pharmaceuticals Corporation
Morris Plains, New Jersey Company-level
Human Cellular, Tissue, and Gene Therapies Not posted Voluntary Action Indicated (VAI)
2022-09-21
Novartis d.o.o.
Menges Company-level
Drug Quality Assurance Not posted No Action Indicated (NAI)
2022-08-30
Novartis Pharma AG
Basel Town Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2025-07-11
Novartis Pharmaceuticals S.R.L.
Targu Mures Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2023-08-26
Novartis Pharmaceuticals S.R.L.
Targu Mures Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Novartis FDA 483 Findings 5 observations · 2023-08-21 → 2024-08-08 ?

By subsystem

  • Documentation & Records 2 (40.0%)
  • Other 1 (20.0%)
  • Laboratory Controls 1 (20.0%)
  • Data Integrity 1 (20.0%)

By severity

  • 5 — Critical: 1
  • 3 — Moderate: 1
  • 2 — Minor: 3
  • Repeat observations: 0

Most severe findings

  • Critical (5) Data Integrity 2024-08-08 21 CFR 211.68(b)
    Computer control of master formula records

    "Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel."

  • Moderate (3) Laboratory Controls 2024-08-08 21 CFR 211.160(b)
    Scientifically sound laboratory controls

    "Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, sampling plans and test procedures designed to assure that components, drug product containers, closures, in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity."

  • Minor (2) Documentation & Records 2024-08-08 21 CFR 211.22(d)
    Procedures not in writing, fully followed

    "The responsibilities and procedures applicable to the quality control unit are not fully followed."

Novartis EMA GMP Compliance 50 certificates

2026-04
2026-04
2026-03
2026-03
2026-02
2026-01
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-12
2025-11
2025-11
2025-11
2025-11
2025-10
2025-10
2025-10
2025-10
2025-10
2025-10
2025-10
2025-10
2025-10
2025-10
2025-04
2025-04
2024-11
2024-09
2023-12
2023-12
2023-12
2023-12
2023-12
2023-12
2023-12
2023-12
2023-12
2023-12
2023-06
2023-02
2023-02
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
sukls112553/2026 Novartis s.r.o. Czechia 2026-04-15 COMPLIANT
sukls112575/2026 Novartis s.r.o. Czechia 2026-04-14 COMPLIANT
BE/GMP/2026/031 Novartis ManufacturingAlternative Name:Novartis Manufacturing N.V. Belgium 2026-03-18 COMPLIANT
484341-105007650 Novartis Pharmaceutical Manufacturing GmbH Austria 2026-03-17 COMPLIANT
DE_BY_05_GMP_2026_0054 Novartis Pharma GmbH Germany 2026-02-10 COMPLIANT
IT/90/H/2026 Novartis Farma S.p.A. Italy 2026-01-16 COMPLIANT
450-8/2026-2 Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. Slovenia 2025-12-19 COMPLIANT
450-15/2026-2 Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. Slovenia 2025-12-19 COMPLIANT
450-16/2026-2 Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. Slovenia 2025-12-19 COMPLIANT
25/23121-34 Novartis Norge AS Norway 2025-12-10 COMPLIANT
401-27/2025-8 Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. Slovenia 2025-12-09 COMPLIANT
450-15/2026-1 Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. Slovenia 2025-12-09 COMPLIANT
450-16/2026-1 Novartis Pharmaceutical Manufacturing LLCAlternative Name:Novartis farmacevtska proizvodnja d.o.o. Slovenia 2025-12-09 COMPLIANT
484326-105148947 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-12-05 COMPLIANT
484326-103675833 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-12-05 COMPLIANT
484296-103675257 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-12-04 COMPLIANT
484296-105553013 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-12-04 COMPLIANT
484296-105579653 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-12-04 COMPLIANT
484296-105654285 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-12-04 COMPLIANT
BE/GMP/2025/157 Novartis PharmaAlternative Name:Novartis Pharma N.V. Belgium 2025-11-24 COMPLIANT
BE/GMP/2025/156 Novartis PharmaAlternative Name:Novartis Pharma N.V. Belgium 2025-11-24 COMPLIANT
BE/GMP/2025/206 Novartis PharmaAlternative Name:Novartis Pharma N.V. Belgium 2025-11-24 COMPLIANT
BE/GMP/2025/207 Novartis PharmaAlternative Name:Novartis Pharma N.V. Belgium 2025-11-24 COMPLIANT
484600-104544504 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-20 COMPLIANT
484600-105471718 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-20 COMPLIANT
DE_BY_05_GMP_2026_0024 Novartis Pharma GmbH Germany 2025-10-14 COMPLIANT
484295-104642509 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-10 COMPLIANT
484295-103675105 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-10 COMPLIANT
484295-104295901 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-10 COMPLIANT
484295-105471003 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-10 COMPLIANT
484295-105582044 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-10 COMPLIANT
484295-105600304 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-10 COMPLIANT
484295-105619677 Novartis Pharmaceutical Manufacturing GmbH Austria 2025-10-10 COMPLIANT
401-7/2025-5 Novartis Pharmaceutical Manufacturing LLC Slovenia 2025-04-10 COMPLIANT
450-16/2026-3 Novartis Pharmaceutical Manufacturing LLC Slovenia 2025-04-10 COMPLIANT
484496-103501763 Novartis Pharmaceutical Manufacturing GmbH Austria 2024-11-04 COMPLIANT
450-4/2025-1 Novartis Pharmaceutical Manufacturing LLC Slovenia 2024-09-20 COMPLIANT
484295-102362426 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-104659277 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-103890257 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-104484889 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-102504807 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-104299099 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-104466717 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-104090448 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-102485983 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484295-102771143 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-12-14 COMPLIANT
484341-101944492 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-06-27 COMPLIANT
484296-103654468 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-02-15 COMPLIANT
484326-101544917 Novartis Pharmaceutical Manufacturing GmbH Austria 2023-02-13 COMPLIANT
Source: EMA EudraGMDP · Retrieved Nov 21, 2026

Novartis MHRA GMP Compliance 1 certificates

2013-04
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK GMP 4647 Insp GMP 4647/1766568-0003[H] NOVARTIS 94070-06256 2013-04-22 COMPLIANT
Source: MHRA GMDP Database · Retrieved Nov 21, 2026

Japan-accredited overseas site (PMDA)

sterile, biologics, general (non-sterile), packaging/storage only, CGT packaging/storage only · 5 sites · own products, not contract-manufacturing evidence

  • Langkampfen, Austria · Novartis Pharmaceutical Manufacturing GmbH — sterile, biologics, packaging/storage only, CGT packaging/storage only · valid to Jun 30, 2028
  • Puurs-Sint-Amands, Belgium · Novartis Manufacturing NV — sterile · valid to Oct 27, 2029
  • Romania · Novartis Pharmaceuticals S.r.l. — general (non-sterile) · valid to Aug 31, 2030
  • Ljubljana, Slovenia · Novartis Pharmaceutical Manufacturing LLC — sterile, general (non-sterile) · valid to Jul 2, 2028
  • Menges, Slovenia · Novartis Pharmaceutical Manufacturing LLC — biologics, general (non-sterile) · valid to Jul 2, 2028

PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. These approvals cover the company's own products; they are not evidence of contract manufacturing. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)

Clinical Activity 137 studies

NCT07676877 Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care... PHASE1 Not Yet Recruiting NCT07443137 CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) PHASE1 Not Yet Recruiting NCT07493408 Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST... PHASE2 Not Yet Recruiting NCT07250087 Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse... PHASE1 Recruiting NCT06964958 177LuPSMA in Renal Cell Carcinoma PHASE2 Active Not Recruiting NCT05469828 Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With... PHASE1/PHASE2 Not Yet Recruiting NCT06456138 Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC PHASE1/PHASE2 Not Yet Recruiting NCT06430671 Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis PHASE1 Completed NCT06395402 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry PHASE2 Recruiting NCT05567055 Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases... PHASE2 Withdrawn NCT05714891 Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer PHASE2 Active Not Recruiting NCT06662825 Real World Patient Characteristics and Treatment Patterns From Crizanlizumab... NA Completed NCT06662825 Real World Patient Characteristics and Treatment Patterns From Crizanlizumab... NA Completed NCT05472220 Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and... PHASE1 Withdrawn NCT06271369 Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study. NA Completed NCT05435846 Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell... PHASE1 Terminated NCT04894370 Combination of Spartalizumab, mDCF and Radiotherapy in Patients With... PHASE2 Recruiting NCT05479448 Predictive Factors for Treatment Response in Patients With Newly-diagnosed... NA Recruiting NCT05199961 Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With... NA Terminated NCT04890236 Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With... EARLY_PHASE1 Completed
+ 117 more studies
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business (100 postings on Nov 20, 2026), and we can't yet tell which of those roles belong to it. Why: the group's board only shows its ~100 newest postings across all units, so we can't separate this business's roles. We'd rather show no number than one that isn't really this company's.
Source: novartis.wd3.myworkdayjobs.com · Checked Nov 20, 2026

Financial Intelligence

6-K 2026-09-08 0 keyword mentions
6-K 2026-09-04 0 keyword mentions
6-K 2026-09-01 0 keyword mentions
6-K 2026-07-21 0 keyword mentions
6-K 2026-06-11 1 keyword mentions
"These results validate the dosing regimen implemented in our Phase III trial and lend further evidence of the potential for del-brax to have a significant impact for people with FSHD,” said Nazem Atassi, Global Head, Neuroscience and Gene Therapy Development, Novartis."
6-K 2026-04-28 0 keyword mentions
6-K 2026-03-18 0 keyword mentions
6-K 2026-02-04 0 keyword mentions
6-K 2026-02-04 0 keyword mentions
20-F 2026-02-04 24 keyword mentions
"We face a challenge to attract and retain top talent in several areas, including biology, immunology, chemistry, clinical development, drug manufacturing, data, digital and IT, including AI, oncology, and advanced therapy platforms (i.e., gene and cell therapy, radioligand therapy, and xRNA)."
"In addition, we manufacture and sell a number of sterile products, biologic products, and products that involve advanced therapy platforms, such as gene and cell therapy, radioligand therapy, and xRNA, or require a supply of highly specialized raw materials, such as cell lines, tissue samples, bacteria, viral strains, and radioisotopes."
"The T315I mutation causes resistance to most available TKI therapies, and, as a result, patients with this mutation would otherwise have limited treatment options • Zolgensma (onasemnogene abeparvovec)/ Itvisma (onasemnogene abeparvovec-brve) is a one-time gene therapy designed to address the genetic root cause of spinal muscular atrophy (SMA) by replacing the function of the missing or nonworking SMN1 gene."
6-K 2025-11-25 5 keyword mentions
"“The SMA disease landscape has dramatically changed over the last six years, when the first gene therapy was approved."
"Novartis has an exclusive, worldwide license with Nationwide Children's Hospital to both the intravenous and intrathecal delivery of adeno-associated virus 9 (AAV9) gene replacement therapy for the treatment of all types of SMA; an exclusive, worldwide license from REGENXBIO for any recombinant AAV vector in its intellectual property portfolio for the in vivo gene replacement therapy treatment of SMA in humans; an exclusive, worldwide licensing agreement with Généthon for in vivo delivery of AAV"
6-K 2025-11-20 0 keyword mentions
6-K 2025-11-05 0 keyword mentions
6-K 2025-10-28 0 keyword mentions
6-K 2025-10-27 0 keyword mentions
6-K 2025-09-30 0 keyword mentions
6-K 2025-08-11 0 keyword mentions
6-K 2025-07-17 0 keyword mentions
6-K 2025-07-17 0 keyword mentions
6-K 2025-06-02 0 keyword mentions
6-K 2025-04-29 0 keyword mentions
6-K 2025-04-03 0 keyword mentions
6-K 2025-03-28 0 keyword mentions
6-K 2025-01-31 0 keyword mentions
6-K 2025-01-31 0 keyword mentions
20-F 2025-01-31 28 keyword mentions
"We face a challenge to attract and retain top talent in several areas, including biology, immunology, chemistry, clinical development, drug manufacturing, data, digital and IT, oncology, and advanced therapy platforms (i.e., gene and cell therapy, radioligand therapy and xRNA) and to maintain and strengthen our employer reputation."
"In addition, we manufacture and sell a number of sterile products, biologic products and products that involve advanced therapy platforms, such as gene and cell therapy, radioligand therapy, and xRNA, all of which are particularly complex and involve highly specialized manufacturing technologies."
"In addition, we manufacture and sell a number of sterile products, biologic products, and products that involve advanced therapy platforms, such as gene and cell therapy, radioligand therapy, and xRNA, all of which are particularly complex and involve highly specialized manufacturing technologies."
6-K 2024-12-30 10 keyword mentions
"OAV101 IT is the first investigational gene therapy to provide clinical benefit in treatment-naïve patients with SMA aged two and older with a positive risk benefit profile"
"7 The results from the Phase III STEER study add to the clinical data and emerging real-world evidence for the use of one-time gene therapy to treat SMA."
"About OAV101 IT Intrathecal onasemnogene abeparvovec (OAV101 IT) is an investigational, one-time gene therapy for patients with spinal muscular atrophy (SMA)."
6-K 2024-11-25 0 keyword mentions
6-K 2024-10-29 0 keyword mentions
6-K 2024-10-29 0 keyword mentions
6-K 2024-09-18 0 keyword mentions
6-K 2024-09-17 0 keyword mentions
6-K 2024-08-08 0 keyword mentions
6-K 2024-07-18 0 keyword mentions
6-K 2024-04-23 0 keyword mentions
Source: SEC EDGAR · Retrieved Nov 21, 2026

Company Signals 20 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-05-06
Novartis Plans Closure Of Wehr Manufacturing Site By 2028 - RTTNews
Novartis Plans Closure Of Wehr Manufacturing Site By 2028  RTTNews
general 2026-05-05
Novartis to close German manufacturing site, cutting 220 jobs - Fierce Pharma
Novartis to close German manufacturing site, cutting 220 jobs  Fierce Pharma
facility_expansion 2026-05-05
Novartis to site seventh new facility in North Carolina - European Pharmaceutical Review
Novartis to site seventh new facility in North Carolina  European Pharmaceutical Review
general 2026-05-05
Biopharma bites: FDA withholds vaccine data, plus staffing cuts for Novartis, Gilead - FirstWord Pharma
Biopharma bites: FDA withholds vaccine data, plus staffing cuts for Novartis, Gilead  FirstWord Pharma
facility_expansion 2026-05-04
Novartis to Add New Facility in Morrisville, NC - Contract Pharma
Novartis to Add New Facility in Morrisville, NC  Contract Pharma
general 2026-05-03
Novartis taps North Carolina as new manufacturing hub location - MSN
Novartis taps North Carolina as new manufacturing hub location  MSN
facility_expansion 2026-05-01
Novartis unveils North Carolina API plant as final piece of $23B US expansion - BioSpace
Novartis unveils North Carolina API plant as final piece of $23B US expansion  BioSpace
general 2026-04-30
Novartis rounds out $23B US investment push with plans for North Carolina API plant - Fierce Pharma
Novartis rounds out $23B US investment push with plans for North Carolina API plant  Fierce Pharma
general 2026-04-30
Novartis to build Morrisville pharma facility as part of $23 billion push - CBS 17
Novartis to build Morrisville pharma facility as part of $23 billion push  CBS 17
facility_expansion 2026-04-30
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility - GlobeNewswire
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility  GlobeNewswire
facility_expansion 2026-04-30
Novartis unveils North Carolina factory as final new build in $23B US expansion - Endpoints News
Novartis unveils North Carolina factory as final new build in $23B US expansion  Endpoints News
general 2026-04-30
Novartis announces new API manufacturing facility in North Carolina - StreetInsider
Novartis announces new API manufacturing facility in North Carolina  StreetInsider
facility_expansion 2026-04-30
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility - marketscreener.com
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility  marketscreener.com
general 2026-04-30
Novartis to open new drug manufacturing facility in Morrisville, North Carolina - ABC11 Raleigh-Durham
Novartis finalizes new drug manufacturing facility in Morrisville, North Carolina  ABC11 Raleigh-Durham
facility_expansion 2026-04-30
Novartis finalizes US manufacturing and R&D expansion plan - The Pharma Letter
Novartis finalizes US manufacturing and R&D expansion plan  The Pharma Letter
facility_expansion 2026-04-30
Novartis (NVS) Expands Manufacturing with New Facility in North Carolina - GuruFocus
Novartis (NVS) Expands Manufacturing with New Facility in North Carolina  GuruFocus
general 2026-04-30
Novartis to build Morrisville pharma facility as part of $23 billion push - CBS 17
Novartis to build Morrisville pharma facility as part of $23 billion push  CBS 17
general 2026-04-30
Manufacturing Insights: Novartis’ Next Move - DCAT Value Chain Insights
Manufacturing Insights: Novartis’ Next Move  DCAT Value Chain Insights
general 2026-04-30
Novartis to open API manufacturing facility in Morrisville - BioProcess International
Novartis to open API manufacturing facility in Morrisville  BioProcess International
facility_expansion 2026-04-30
Novartis Finalizes US Expansion with Seventh Facility to Strengthen End-to-End Drug Manufacturing - BioPharm International
Novartis Finalizes US Expansion with Seventh Facility to Strengthen End-to-End Drug Manufacturing  BioPharm International

Frequently Asked Questions About Novartis

How many FDA inspections does Novartis have on record?
CDMO Signal tracks 19 FDA inspections for Novartis, sourced from the FDA inspection database. See the full inspection history above.
Has Novartis received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Novartis.
Does Novartis hold EMA or MHRA GMP certificates?
CDMO Signal tracks 50 EMA and 1 MHRA GMP certificates for Novartis.
How many clinical programs is Novartis linked to?
Novartis is associated with 137 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Novartis's CDMO Signal Score?
Novartis has a Signal Score of 85/100, based on quality, operations, financial stability, and capacity data.
Evaluating Novartis for a manufacturing program?
Use the free AI matchmaker to compare Novartis against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Gene Therapy CDMOs →

Similar CDMOs

Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.7
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody

Compare Novartis with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Novartis
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.